التفاصيل البيبلوغرافية
| العنوان: |
A phase 2 study of vatalanib in metastatic melanoma patients |
| المؤلفون: |
Cook, Natalie1, Basu, Bristi1, Biswas, Swethajit1, Kareclas, Paula1, Mann, Colette1, Palmer, Cheryl1, Thomas, Anne2, Nicholson, Steve2, Morgan, Bruno2, Lomas, David1, Sirohi, Bhawna1, Mander, Adrian P.3, Middleton, Mark4, Corrie, Pippa G.1 pippa.corrie@addenbrookes.nhs.uk |
| المصدر: |
European Journal of Cancer. Oct2010, Vol. 46 Issue 15, p2671-2673. 3p. |
| مصطلحات موضوعية: |
*HEALTH outcome assessment, *CANCER treatment, *MELANOMA, *NEUROENDOCRINE tumors, *DRUG efficacy, *PATIENTS, *EVALUATION of clinical trials, *MELANOMA diagnosis, *METASTASIS, *THERAPEUTIC use of monoclonal antibodies, *CANCER patients, *CONFIDENCE intervals, *DRUG toxicity, *MAGNETIC resonance imaging, *MONOCLONAL antibodies, *TUMORS, *PATIENT selection, *DIAGNOSIS |
| مصطلحات جغرافية: |
EUROPE |
| مستخلص: |
Abstract: Background: A phase 2 study of vatalanib (PTK787/ZK222584) an oral tyrosine kinase inhibitor of VEGFR 1, 2 and 3 was undertaken in patients with metastatic melanoma. Methods: Adults with pathologically confirmed metastatic melanoma, WHO Performance status 0–2, and adequate haematological, hepatic and renal function, were treated with vatalanib until disease progression. The trial used Fleming’s single stage design. Results: Tumour control rate (CR+PR+SD) was 35% at 16weeks, with objective response seen in only 1 patient. Median progression-free survival was 1.8months (95% CI 1.8–3.7months) and median overall survival was 6.5months (95% CI 3.9–10.2months). Conclusion: Vatalanib stabilised disease in a proportion of patients, although overall survival was disappointing. [Copyright &y& Elsevier] |
| قاعدة البيانات: |
Academic Search Index |
